Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968680 · ClinicalTrials.gov registry record · Phase 1
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02968680 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 5 participants.
The verdict
NCT02968680, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that may make it easier to see if the tumor cells have spread to the sentinel lymph node using an ultrasound.
Interventions
- PROCEDURE Sentinel Lymph Node Biopsy
- DRUG Sonazoid
- DEVICE Ultrasonography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968680
The ClinicalTrials.gov registry entry for NCT02968680 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sentinel Lymph Node Biopsy is the first listed.
NCT02968680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968680 about?
NCT02968680 is a clinical study titled "Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma". This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that may make it easier to see if the tumor cells have spread to the sentinel lymph node using an ultrasound.
What is the current status of trial NCT02968680?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-04-26. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT02968680?
The interventions under investigation include: Sentinel Lymph Node Biopsy (PROCEDURE), Sonazoid (DRUG), Ultrasonography (DEVICE).
Who is sponsoring clinical trial NCT02968680?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.